Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.

乌斯特基努马 医学 克罗恩病 内科学 临床试验 随机对照试验 疾病 随机化 外科 物理疗法
作者
Silvio Danese,Severine Vermeire,Geert D'Haens,Julian Panés,Axel Dignass,Fernando Magro,Maciej Nazar,Manuela Le Bars,Marjolein Lahaye,Lioudmila Ni,Ivana Bravata,Frederic Lavie,Marco Daperno,Milan Lukáš,Alessandro Armuzzi,Mark Löwenberg,Daniel R Gaya,Laurent Peyrin-Biroulet
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (4): 294-306
标识
DOI:10.1016/s2468-1253(21)00474-x
摘要

A treat-to-target strategy, in which strictly defined treatment targets facilitate decision making in clinical practice, is advocated as an optimised management approach for some chronic disorders. The aim of the STARDUST trial was to assess whether a treat-to-target strategy with early endoscopy, regular biomarker and clinical symptom monitoring, and dose intensification for persistent inflammatory activity, was more successful in achieving endoscopic improvement at week 48 than a clinically driven maintenance strategy in patients with moderate-to-severe active Crohn's disease receiving ustekinumab.This open-label, multicentre, randomised phase 3b trial included adults with active, moderate-to-severe Crohn's disease (Crohn's Disease Activity Index [CDAI] 220-450 and Simple Endoscopic Score in Crohn's Disease [SES-CD] ≥3) for whom conventional therapy or one biologic therapy, or both, had failed. Patients received intravenous ustekinumab approximating 6 mg/kg at baseline and subcutaneous ustekinumab 90 mg at week 8. At week 16, patients with a CDAI improvement of 70 or more points from baseline were randomly assigned (1:1) to receive standard-of-care or treat-to-target maintenance treatment through week 48. Randomisation was balanced by using randomly permuted blocks and was stratified by biologic history status and baseline SES-CD score. All patients who signed informed consent, who were not screening failures, and who received at least one dose of study treatment were included in week 16 analyses. All patients included in week 16 analyses and randomly assigned to one of the maintenance treatment regimens were included in the week 48 efficacy and safety analyses (ie, on an intention-to-treat basis). Patients assigned to the treat-to-target arm received ustekinumab every 12 weeks or every 8 weeks based on SES-CD improvement from baseline and could escalate to every 4 weeks through week 48 if prespecified targets were missed. Patients assigned to the standard-of-care arm received ustekinumab every 12 weeks or every 8 weeks; those receiving treatment every 12 weeks could escalate per European labelling. The primary efficacy endpoint was endoscopic response at week 48 (SES-CD score ≥50% decrease from baseline), analysed by non-responder imputation. This trial is registered at ClinicalTrials.gov, NCT03107793, and is active but not recruiting.498 patients received standard induction treatment, of whom 440 were randomly assigned to the treat-to-target group (n=219) or the standard-of-care group (n=221). At week 48, there was no significant difference in endoscopic response (83 [38%] of 219 patients vs 66 [30%] of 221 patients; p=0·087), endoscopic remission (25 [11%] vs 32 [15%]; p=0·334), mucosal healing (31 [14%] vs 37 [17%]; p=0·449), and clinical remission (135 [62%] vs 154 [70%]; p=0·072) between the two groups; clinical response was significantly lower in the treat-to-target group than in the standard-of-care group (149 [68%] vs 172 [78%]; p=0·020). Other endoscopic, clinical, and biomarker outcomes were generally not significantly different between groups. The most commonly reported treatment-emergent adverse events were nasopharyngitis (29 [13%] of 219 patients in the treat-to-target group vs 29 [13%] of 221 patients in the standard-of-care group), abdominal pain (23 [11%] vs 19 [9%]), arthralgia (24 [11%] vs 19 [9%]), and headache (24 [11%] vs 21 [10%]).Timely escalation of ustekinumab therapy for patients with Crohn's disease, based on early endoscopic response, clinical symptoms, and biomarkers, did not result in significantly better endoscopic outcomes at week 48 than symptom-driven decisions alone. Future studies need to confirm if some subgroups of patient might benefit from a treat-to-target strategy with ustekinumab.Janssen-Cilag.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
司空悒完成签到,获得积分10
1秒前
vanilla完成签到 ,获得积分10
5秒前
平淡的寄风完成签到,获得积分10
6秒前
114422完成签到,获得积分10
7秒前
努力写论文完成签到 ,获得积分10
7秒前
8秒前
陶醉聪展完成签到 ,获得积分10
9秒前
sally完成签到 ,获得积分10
11秒前
两半桃花发布了新的文献求助10
13秒前
13秒前
诸笑白完成签到,获得积分10
15秒前
顾矜应助孤独映天采纳,获得10
15秒前
喵了个咪完成签到 ,获得积分10
16秒前
丸子完成签到 ,获得积分10
17秒前
青檬完成签到 ,获得积分10
19秒前
两半桃花完成签到,获得积分10
20秒前
Alan完成签到,获得积分10
22秒前
美丽完成签到 ,获得积分10
23秒前
绵羊完成签到,获得积分10
24秒前
小小组完成签到,获得积分10
25秒前
李爱国应助科研通管家采纳,获得10
26秒前
星河长明应助科研通管家采纳,获得10
26秒前
二三发布了新的文献求助10
28秒前
Heather完成签到 ,获得积分10
29秒前
默默的橘子完成签到 ,获得积分20
30秒前
hhh完成签到,获得积分10
30秒前
cistronic完成签到,获得积分10
31秒前
聚甲烯吡络烷酮完成签到,获得积分10
31秒前
Seb完成签到 ,获得积分10
32秒前
yshj完成签到 ,获得积分10
33秒前
彪壮的冰双完成签到,获得积分10
35秒前
35秒前
gaga完成签到,获得积分10
35秒前
踏雪飞鸿完成签到,获得积分10
37秒前
Sunny完成签到,获得积分10
37秒前
悦耳的妙竹完成签到,获得积分10
42秒前
孤独映天发布了新的文献求助10
42秒前
无情的匪完成签到 ,获得积分10
43秒前
魔幻千秋完成签到,获得积分0
45秒前
肉肉完成签到 ,获得积分10
46秒前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Cross-Cultural Psychology: Critical Thinking and Contemporary Applications (8th edition) 800
Counseling With Immigrants, Refugees, and Their Families From Social Justice Perspectives pages 800
マンネンタケ科植物由来メロテルペノイド類の網羅的全合成/Collective Synthesis of Meroterpenoids Derived from Ganoderma Family 500
岩石破裂过程的数值模拟研究 500
Electrochemistry 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2374225
求助须知:如何正确求助?哪些是违规求助? 2081558
关于积分的说明 5216569
捐赠科研通 1809196
什么是DOI,文献DOI怎么找? 902933
版权声明 558406
科研通“疑难数据库(出版商)”最低求助积分说明 482119